Early breast cancer no longer needs to raise fear in women of disfigurement and months of debilitating treatment recognized by a bald head and a wig. Your future depends on knowing all the facts about breast cancer and its treatments.
Breast cancer is one of the most common cancers in the world. About 246,660 cases of female invasive breast cancer are predicted for 2016 in the USA alone. Breast cancer is caused by cells within the breast tissue mutating and creating a growth called a "tumor". Many may feel the tumor as a lump in the breast. When detected as a small mass, for example 1 cm in size, and there is no evidence of spread to the lymph nodes under the arm, a simple surgical removal called "lumpectomy" can be done as an outpatient surgery. Such early breast cancers can have high success rates. Today, however, it has become customary that patients with early breast cancer also undergo chemotherapy and radiotherapy for six to nine months after the lumpectomy in a therapy called "adjuvant."
The future of women with early breast cancer becomes more worrisome, however, if her breast mass is larger and particularly if the cancer is found in lymph nodes under her arm. Despite the latest adjuvant therapies, patients with cancer that has spread to the lymph nodes do not do well.
Recently, the Susan G. Komen Foundation, who sponsors the nationwide "Race for the Cure", published some startling findings on their website. In women ages 60 to 69, adjuvant chemo and radiotherapy achieved only a 3% improvement in survival compared to women who chose to do nothing after the lumpectomy. In other age groups, women do only slightly better.
The National Cancer Institute published disturbing statistics that over half of women with stage IIIB/C breast cancer will succumb to the disease despite the standard adjuvant therapy after lumpectomy. Without lumpectomy, at all stages, most patients succumb quickly.
In response to the inefficacy of conventional adjuvant therapy, a powerful new therapy with no side effects was developed by Dr. Kenneth Matsumura. It was recently announced that his clinics will begin offering Side Effect-Free Chemotherapy® (SEF Chemo® - pronounced "safe") as an alternative to the failed conventional adjuvant therapy. Where adjuvant therapy can entail more than six months of disabling chemo and radiation, SEF Chemo® has a standard eight-week therapy and patients can continue working while undergoing treatment. There are virtually no side effects— no loss of hair, nausea, vomiting, or diarrhea. Best of all, SEF Chemo® maintains a healthy immune system so the body can join in the fight against cancer.
SEF Chemo® was developed by a celebrated medical inventor, Dr. Kenneth Matsumura, Chairman and Medical Director of ALIN Foundation, in Berkeley, California.— It has been under development for over 30 years and early on received FDA approval for clinical trial in a record-breaking time of four days.
The historical achievements of SEF Chemo® in treatment of diverse types of cancer is nothing short of remarkable. In the beginning of the phase II clinical trial, all initial patients with lung, breast, and blood cancers went into long-term remissions that rarely happen with conventional chemotherapy. The longest survivor is a stage IV breast cancer patient suffering with metastasis that had spread to the liver. She remains completely free of cancer over a decade later. In general, stage IV cancers have been considered by oncologists to be incurable and the best they can achieve is adding a few extra months of life through toxic chemotherapy.
SEF Chemo® uses a new combination of the most effective FDA approved drugs and chemo agents in an innovative schedule of medications to protect the patient but eradicate the cancer. New doctors and nurses require about two years of training to master the technique.
SEF Chemo® is being offered by international centers in the United States, Mexico, and Canada. As more doctors are trained, more regional centers will be authorized. With over eight million cancer patients worldwide, strong efforts are being made to expand the treatment capacity in a quiet and orderly manner so as to not disturb current patients being treated. For more information, please visit our website at www.berkeley-institute.com.
On a regular basis, this website will publish up-to-date information with annotated medical journal source on topics such as:
The pros and cons of breast radiotherapy: “proven to reduce local recurrence after lumpectomy but without effect on survival; what are the chances of developing a new breast cancer in the future from the therapy.” Click Here to read the article.
The truth about mammograms: Is there actual evidence that they can save lives? Can mammogram radiation cause cancer?
Breast cancer in younger women: New research found breast cancer in pre-menopausal women to be histologically more aggressive. What can be done?
HER2 and "triple negative" breast cancers: Are they more troublesome?
Lumpectomy: Is it necessary? A report on women who chose to forgo adjuvant therapy.
The consequence of delaying adjuvant therapy after lumpectomy: are there any?
Hormone-suppressive drugs after lumpectomy and adjuvant therapy: are they necessary?
Latest cancer assessment tools:— Maintrac® and Oncoblot®. What are their roles during therapy and possible detection of recurrence?
Click Here to Read More about SEF Chemotherapy®